REGENXBIO Inc. (RGNX)

Market Cap	510.19M +41.6%
Revenue (ttm)	170.44M +104.5%
Net Income	-193.88M
EPS	-3.76
Shares Out	51.61M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,112,257
Open	10.56
Previous Close	10.38
Day's Range	9.87 - 10.65
52-Week Range	5.04 - 16.19
Beta	1.14
Analysts	Strong Buy
Price Target	28.75 (+190.85%)
Earnings Date	Mar 5, 2026

About RGNX

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-12...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 17, 2015
• Employees: 371
• Stock Exchange: NASDAQ
• Ticker Symbol: RGNX
• Website: https://www.regenxbio.com

Financial Performance

In 2025, REGENXBIO's revenue was $170.44 million, an increase of 104.54% compared to the previous year's $83.33 million. Losses were -$193.88 million, -14.63% less than in 2024.

Analyst Summary

According to 8 analysts, the average rating for RGNX stock is "Strong Buy." The 12-month stock price target is $28.75, which is an increase of 190.85% from the latest price.

Price Target

$28.75

(190.85% upside)

Analyst Consensus: Strong Buy